This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.
Becton, Dickinson (BDX) Tops Q3 Earnings, Misses On Revenues
by Zacks Equity Research
Impressive results in Becton, Dickinson's (BDX) medical segment reflect strong performance in the Medication and Procedural Solutions, Diabetes Care and Pharmaceutical Systems units.
Becton, Dickinson (BDX) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Becton, Dickinson's (BDX) second-quarter performance faces risks from unfavorable foreign exchange rate.
AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.
MedTech Thriving on Consolidation & Expansion: Stocks to Buy
by Zacks Equity Research
The industry has some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation.
Top Analyst Reports for Procter & Gamble, Verizon & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Verizon (VZ) and Citigroup (C).
Why Is Becton, Dickinson (BDX) Up 3% Since the Last Earnings Report?
by Zacks Equity Research
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for May 4, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).
Becton, Dickinson (BDX) Beats On Earnings & Revenues In Q2
by Zacks Equity Research
Becton, Dickinson's adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 7 cents and increased 5.5% from $2.18 posted in the year-ago quarter.
Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More
by Zacks Equity Research
The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things.
Is a Surprise Coming for Becton (BDX) This Earnings Season?
by Zacks Equity Research
Becton (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can CVS Health (CVS) Spring a Surprise this Earnings Season?
by Zacks Equity Research
CVS Health Corporation (CVS) is scheduled to report its first-quarter 2017 results before the opening bell on May 2.
Will LabCorp (LH) Pull a Surprise this Earnings Season?
by Zacks Equity Research
Laboratory Corp. of America Holdings (LH) or LabCorp is expected to report first-quarter 2017 results before the market opens on Apr 25.
Becton, Dickinson and Company (BDX) Up 3.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Becton, Dickinson and Company (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for March 3, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Caterpillar (CAT) and Broadcom (AVGO).
Becton, Dickinson Launches BD Resolve Early Access Program
by Zacks Equity Research
Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.
Becton, Dickinson (BDX) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2017 earnings of $2.33 per share, which beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter.
Becton, Dickinson (BDX) Beats Q1 Earnings & Revenues
by Zacks Equity Research
Becton, Dickinson???s adjusted earnings of $2.33 per share beat the Zacks Consensus Estimate by 22 cents.
Becton, Dickinson (BDX) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Becton, Dickinson and Company (BDX) is set to report first-quarter fiscal 2017 earnings results on Feb 2.
Becton, Dickinson Commercially Launches Precise WTA Kits
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.
Top 4 Research Reports for August 11, 2016
by Sheraz Mian
Today's must-read reports are for Priceline (PCLN), Time Warner (TWX), Public Storage (PSA) and Southern Company (SO).